In the TROPION-Lung01 Phase 3 trial, Datopotamab Deruxtecan demonstrated a median overall survival of 14.6 months for patients with advanced nonsquamous non-small cell lung cancer.
KaliVir is able to produce novel, potent oncolytic Vaccinia viruses with high replication ability and enhanced capabilities for intravenous administration and dissemination.
Sep 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
The article reported on Phase 2 clinical trial data for the use of the monoclonal antibody Lu AG09222ALD-1910 targeting pituitary adenylate cyclase-activating polypeptide (PACAP) in the treatment of migraine.
The global HIV drug market is highly competitive, with multiple pharmaceutical companies collaborating in research and commercialization to provide more effective treatment options.
Relay Therapeutics has announced encouraging interim results for RLY-2608, the initial investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα.